Investigating how chorioamnionitis affects lung health in newborns
Official title: IL17 mediates chorioamnionitis induced lung damage
Funded at University of Alabama at Birmingham · NIH-10984592 · Data updated 2026-11-12
This study is looking at how a condition called chorioamnionitis affects the lungs of preterm babies, and it aims to find ways to help improve their lung health by checking their immune responses and lung function.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $171,095 |
| NIH project number | 1K08HL171892-01A1 |
| Project ID | NIH-10984592 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are preterm infants born before 32 weeks of gestation, particularly those exposed to chorioamnionitis.
✕Less likely to help
Patients who are not preterm or who do not have a history of chorioamnionitis may not benefit from this research.
What this research studies
This research focuses on understanding the impact of chorioamnionitis, a condition that can lead to preterm birth, on lung development and function in infants. The study will involve a cohort of preterm infants, some of whom have been exposed to chorioamnionitis, to analyze immune responses and lung mechanics. Researchers will collect blood and tracheal aspirate samples to measure specific immune cell activity and cytokine levels, aiming to establish a connection between these factors and lung health outcomes. The goal is to identify potential therapeutic targets to improve lung function in affected infants.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing lung damage in infants born preterm due to chorioamnionitis.
How similar studies have gone: Previous research has indicated that targeting immune pathways may improve outcomes in similar conditions, suggesting potential for success in this approach.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Jain, Viral G — University of Alabama at Birmingham
- Study coordinator: Jain, Viral G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.